HIV and HCV infection among injecting drug users

被引:0
作者
Hagan, H
Jarlais, DCD
机构
[1] Publ Hlth Seattle & King Cty, Seattle, WA 98104 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Beth Israel Deaconess Med Ctr, Inst Chem Dependency, New York, NY 10003 USA
来源
MOUNT SINAI JOURNAL OF MEDICINE | 2000年 / 67卷 / 5-6期
关键词
substance abuse; injection drug use; HIV; HCV; epidemiology;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are the two blood-borne pathogens most commonly transmitted among injection drug users via multi-person use of syringes and other injection equipment. However, important differences exist in the epidemiology of HIV and HCV within different populations of intravenous drug users. Methods: A literature review was carried out to summarize publications describing the epidemiology and natural history of HIV and HCV in injection drug users. Results: Among injection drug users worldwide, HIV prevalence varies from < 5% to > 80%, with annual HIV incidence between < 1% and 50%. More consistency is shown in HCV prevalence (50-90%) and incidence (10-30% per year). Host, environmental and viral factors that favor rapid spread of HCV among IDUs suggest that HCV infection in a population of injection drug users may become endemic over a relatively shea period of time. Lower transmission efficiency for HIV also indicates that its spread among injection drug users may be somewhat slower. Conclusions: Successful efforts to prevent transmission of blood-borne viruses among IDUs typically result in risk reduction; however, no intervention has resulted in elimination of risk behavior. To reduce HIV transmission, risk reduction may be sufficient, whereas control of HCV may necessitate the use of injection practices that guarantee elimination of exposure to equipment contaminated with even small amounts of blood.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 74 条
[1]   Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference [J].
Ahmed, A ;
Keeffe, EB .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 :S12-S18
[2]   The importance of preventing hepatitis C virus infection among injection drug users in the United States [J].
Alter, MJ ;
Moyer, LA .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 :S6-S10
[3]  
ANDERSON RA, 1995, INFECT DIS HUMANS
[4]  
[Anonymous], 1992, AIDS, V6, P421
[5]  
BURNS SM, 1996, J INFECTION, V3, P253
[6]  
CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9
[7]  
Celentano DD, 1999, AM J EPIDEMIOL, V149, P558, DOI 10.1093/oxfordjournals.aje.a009852
[8]  
CHAMOT E, 1992, AIDS, V6, P430, DOI 10.1097/00002030-199204000-00013
[9]   RISK-FACTORS FOR HIV-1 SEROCONVERSION AMONG INJECTION-DRUG USERS - A CASE-CONTROL STUDY [J].
CHITWOOD, DD ;
GRIFFIN, DK ;
COMERFORD, M ;
PAGE, JB ;
TRAPIDO, EJ ;
LAI, SG ;
MCCOY, CB .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (11) :1538-1542
[10]   RISK-FACTORS AND HIV SEROPOSITIVITY AMONG INJECTING DRUG-USERS IN BANGKOK [J].
CHOOPANYA, K ;
VANICHSENI, S ;
JARLAIS, DCD ;
PLANGSRINGARM, K ;
SONCHAI, W ;
CARBALLO, M ;
FRIEDMANN, P ;
FRIEDMAN, SR .
AIDS, 1991, 5 (12) :1509-1513